Q-omics provides the consensus-scored TESC profile across patient tissues and cancer cell-line models. TESC expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TESC is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, TESC protein abundance shows 21,185 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where TESC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TESC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TESC survival associations across molecular data types. TESC RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TESC RNA expression–survival associations across cancer types. High TESC expression shows unfavorable associations in UVM, LIHC, LUAD and ESCA, but favorable associations in HNSC and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TESC RNA expression.
This table summarizes TESC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TESC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TESC shows lower tumor expression in HNSC and higher tumor expression in COAD, THCA, LIHC, LUAD and READ. The COAD box plot shows higher TESC RNA expression in tumor versus normal tissue (log2 FC = +4.498, t-test p < 0.001).
This table shows molecular features associated with TESC in patient tissues and cancer cell lines. In patient samples, TESC shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TESC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
